Efficacy and safety of rh-endostatin combined with docetaxel in the treatment of patients with advanced nonsmall cell lung cancer

Abstract

Objective To analyze the efficacy and safety of rh-endostatin combined with docetaxel in the treatment of patients with advanced non-small cell lung cancer （ NSCLC ） .Methods 96 advanced NSCLC patients were selected and were randomly divided into two groups .The combined group was given rh-endostatin combined with docetaxel （n=50）,the control group was given docetaxel alone （n=46）.The response rate（RR）,disease control rate（DCR）,the variation of ECOG,the relief rate of clinical symptoms and side reactions were evaluated .Results The RR of combined group and control group were 62.0% and 37.0%,respectively,and the difference was statisti-cally significant（χ2 =6.010,P=0.014）.The DCR of the two groups were 92.0% and 78.3%,the difference was not statistically significant （χ2 =3.631,P=0.057）.After therapy,the ECOG score was （0.81 ±0.46）points in the combined group and （1.09 ±0.53）points in the control group,which were all markedly reduced compared with before treatment （t=2.360,P=0.034;t=6.323,P=0.008）,and statistical difference existed between the two groups after treatment （t=5.971,P=0.018）.The relief rates of clinical symptoms in the combined group were higher than those in the control group：the relief rates of cough were 82.0% and 63.0%,the relief rates of short breath were 88.0%and 67.4%,the relief rates of hemoptysis were 52.0% and 30.4%,and the relief rates of pain were 68.0% and 47.8%,the differences were statistically significant （χ2 =4.360,P=0.037;χ2 =5.954,P=0.015;χ2 =4.584,P=0.032;χ2 =4.012 P=0.045）.The incidence rates of adverse reactions of the two groups were 62.0%and 71.7%, respectively,there was no statistical difference （χ2 =1.023,P=0.312）.Nausea,vomiting,fatigue and bone marrow depression were the main side reactions and there were no statistical differences between the combined group and con -trol group（χ2 =2.304,P〉0.05）.Conclusion Re-endostatin combined with docetaxel in the treatment of patients with advanced NSCLC has higher response rate and disease control rate ,which is well tolerated and effective chemo-therapy drugs for advanced NSCLC patients . Key words: Carcinoma, non-small-cell lung; Drug therapy, combination ; Recombinant human endostatin ; Docetaxel